

## Technology Advisory Interests Register

### Topic: Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346]

Publication Date: 18 June 2026

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Matt Bradley	TAC Committee Member	Direct – financial	I hold shares in AstraZeneca who manufacture durvalumab (a competitor product).	18/06/2025	It was agreed that Matt's declaration would prevent them from participating in discussions on this appraisal
Simon McNamara	TAC Committee Member	Financial	Employed by GSK who is developing medicines in this disease area.	26/02/2026	It was agreed that Simon's declaration would prevent them from participating in discussions on this appraisal
Dr Shobhit Bajjal	Expert	Financial	<ul style="list-style-type: none"> <li>I have received honoraria from Accord for an advisory board.</li> <li>I have received honoraria from Accord, AstraZeneca and Roche for consultancy work.</li> <li>£1,375 – participation in clinical advisory board in</li> </ul>	11/02/2025 09/04/2026	It was agreed that Shobhit's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			relation to chemo-immunotherapy		
Dr Tim Benepal	Expert	Direct - financial	£1,375 – participation in clinical advisory board in relation to chemo-immunotherapy	03/10/2025 09/04/2026	It was agreed that Tim's declaration would not prevent them from providing expert advice to the committee
			Received honoraria from Accord, AstraZeneca, and Roche	09/04/2026	